Unbound MEDLINE

Humoral and cell-mediated immune-responses after administration of a single-shot recombinant hepatitis B surface antigen vaccine formulated with cationic poly(l-lactide) microspheres. Journal of drug targeting [J Drug Target] Journal article

 
TitleHumoral and cell-mediated immune-responses after administration of a single-shot recombinant hepatitis B surface antigen vaccine formulated with cationic poly(l-lactide) microspheres.
Author(s)Saini V, Jain V, Sudheesh MS, Dixit S, Gaur RL, Sahoo MK, Joseph SK, Verma SK, Jaganathan KS, Murthy PK, Kohli D 
InstitutionBiopharmaceuticals Research Laboratory, Deparment of Pharmaceutical Sciences, Dr. Harisingh Gour University, Sagar, Madhya Pradesh, India.
SourceJ Drug Target 2009 Nov 2.
AbstractThe present investigations were aimed to compare the humoral and cell-mediated immune responses between recombinant hepatitis B surface antigens (HBsAg) adsorbed L-PLA microspheres (Ms) vaccine (single-shot) and marketed alum-HBsAg vaccine (two-doses). The blank cationic (cetyltrimethyammoniumbromide) microspheres were prepared by the double emulsion (w/o/w) solvent evaporation technique. The HBsAg was adsorbed onto the surface of blank cationic microspheres. These microspheres were characterized in vitro for their size, shape, adsorption-efficiency, in-process stability, and HBsAg release studies. Specific humoral immune responses (IgM and IgG) and cell-mediated immune responses (cellular-proliferation) assay including release of interferon-gamma (IFN-gamma), interleukin-2 (IL-2), and nitric oxide (NO) from host's cells stimulated with HBsAg or lipopolysaccharide (LPS)/ concanavalin A (con A) in-vitro were determined. Based on these findings, it was concluded that the single injection (using subcutaneous-route) of the polymeric microspheres produced the better immune response (both humoral and cell-mediated) than two injections of a conventional alum-HBsAg vaccine. These data demonstrate high potential of polymeric microspheres for their use as a carrier adjuvant for hepatitis B vaccine.
LanguageENG
Pub Type(s)JOURNAL ARTICLE
PubMed ID19883203
  
Advertise on this site.